百时美施贵宝Bristol Myers Squibb Co. (BMY) 2021年CSR报告「NYSE」.pdf

1、2021 Environmental,Social and Governance ReportProgress against 16+indicators in accordance with the BioPharma Alliance,SASB and GRITable of Contents 3 About Bristol Myers Squibb 9 Ethics,Integrity,Quality and Governance19 Innovation,Equity and Access to Healthcare27 Our People38 Environmental Respo

2、nsibility50 AppendixAbout This ReportThis report is written in accordance with the Biopharma Investor ESG Communications Guidance 2.0,which was developed by the Biopharma Investor ESG Communications Initiative,part of the Biopharma Sustainability Roundtable(BSRT).It was prepared with reference to th

3、e Global Reporting Initiative(GRI)standards and the Sustainability Accounting Standards Board(SASB)standards for the biopharmaceutical sector.This report also includes our Anti-Corruption report using the Norges Bank Investment Management(NBIM)guidance,providing additional transparency to our progre

4、ss in this critical area.Unless otherwise stated,this report details our performance on ESG topics and contains nonfinancial disclosures covering the period from January 1,2021,through December 31,2021.2021 ESG REPORT|2About Bristol Myers SquibbTransforming patients lives through scienceTMWe are a g

5、lobal biopharmaceutical company whose mission is to discover,develop and deliver innovative medicines that help patients prevail over serious diseases.At Bristol Myers Squibb(BMS),we are in the business of medical breakthroughsthe kinds that transform and save patients lives.Our business combines th

6、e agility of biotech with the reach and resources of an established pharmaceutical company to create a leading global biopharma company.We bring a human touch to every treatment we pioneer.With a diverse and promising R&D pipeline,we focus on innovations that drive meaningful change.Our therapeutic